(Q37071195)

18 August 2017

1 reference

title

The use of dexrazoxane for the prevention of anthracycline extravasation injury (English)

1 reference

18 August 2017

Brian B Hasinoff

1

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Investigational Drugs

18 August 2017

published in

1 reference

18 August 2017

volume

17

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

217-223

1 reference

Dexrazoxane use in the prevention of anthracycline extravasation injury

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Extravasation management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Totect: a new agent for treating anthracycline extravasation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane for anthracycline extravasation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Management of anthracycline extravasation injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Evaluation and treatment of chemotherapy extravasation injuries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane (ICRF-187) Protects Cardiac Myocytes Against Doxorubicin by Preventing Damage to Mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Tumor cell death induced by topoisomerase-targeting drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.217

10.1517/13543784.17.2.217

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference